RANOLAZINE
Ranolazine
Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina.
- IUPACName
- (RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide
- CASNumber
- 142387-99-3
- MolecularFormula
- C24H33N3O4
- Synonyms
- RANOLAZINE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethy]piperazine;CVT 303;Ranexa;Renexa;RS 43285-003;1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-
- Application
- For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.
